New 4-Drug cocktail shows promise for Tough-to-Treat myeloma
NCT ID NCT04883242
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 36 times
Summary
This study tests a combination of four drugs (isatuximab, carfilzomib, pomalidomide, and dexamethasone) in 30 adults whose multiple myeloma has returned or is not responding to prior treatments. The goal is to see how well this drug mix shrinks or controls the cancer. Participants must have already tried at least one prior therapy, including lenalidomide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.